Carlos Gomez‐Roca
About
Carlos Gomez‐Roca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Carlos Gomez‐Roca has authored 147 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 39 papers in Molecular Biology. Recurrent topics in Carlos Gomez‐Roca's work include Cancer Immunotherapy and Biomarkers (46 papers), Colorectal Cancer Treatments and Studies (26 papers) and Cancer Genomics and Diagnostics (22 papers). Carlos Gomez‐Roca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (46 papers), Colorectal Cancer Treatments and Studies (26 papers) and Cancer Genomics and Diagnostics (22 papers). Carlos Gomez‐Roca collaborates with scholars based in France, United States and United Kingdom. Carlos Gomez‐Roca's co-authors include Jean‐Pierre Delord, Jean‐Charles Soria, Sarina A. Piha‐Paul, Sanatan Saraf, Bert H. O’Neil, Emilie M.J. van Brummelen, Patrick A. Ott, Andréa Varga, Christophe Le Tourneau and Shari Thomas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Carlos Gomez‐Roca
144 papers receiving 3.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carlos Gomez‐Roca France | 31 | 2.4k | 1.3k | 820 | 796 | 639 | 147 | 4.0k | ||
| Drew Rasco United States | 33 | 2.4k 1.0× | 1.7k 1.3× | 980 1.2× | 870 1.1× | 293 0.5× | 192 | 4.1k | ||
| Peter Langmuir United States | 30 | 1.8k 0.8× | 1.3k 1.0× | 1.6k 2.0× | 888 1.1× | 320 0.5× | 56 | 4.7k | ||
| Steven J. Lemery United States | 26 | 1.8k 0.8× | 545 0.4× | 852 1.0× | 613 0.8× | 482 0.8× | 65 | 3.3k | ||
| Sameek Roychowdhury United States | 29 | 1.6k 0.7× | 1.3k 1.0× | 848 1.0× | 774 1.0× | 657 1.0× | 83 | 3.7k | ||
| Albiruni R. Abdul Razak Canada | 29 | 2.0k 0.8× | 1.1k 0.9× | 1.1k 1.4× | 639 0.8× | 368 0.6× | 96 | 3.5k | ||
| Andréa Varga France | 33 | 3.0k 1.3× | 1.2k 0.9× | 1.2k 1.5× | 816 1.0× | 911 1.4× | 107 | 4.6k | ||
| Alexander N. Shoushtari United States | 34 | 3.3k 1.4× | 1.4k 1.1× | 833 1.0× | 1.6k 2.0× | 315 0.5× | 167 | 4.7k | ||
| Ulrik Lassen Denmark | 36 | 2.2k 0.9× | 1.7k 1.3× | 1.6k 1.9× | 338 0.4× | 644 1.0× | 253 | 4.9k | ||
| Alejandro D. Ricart United States | 24 | 2.5k 1.0× | 1.4k 1.1× | 762 0.9× | 780 1.0× | 170 0.3× | 57 | 4.0k | ||
| Syma Iqbal United States | 29 | 2.0k 0.8× | 901 0.7× | 993 1.2× | 228 0.3× | 679 1.1× | 129 | 3.1k |
Countries citing papers authored by Carlos Gomez‐Roca
Since
Specialization
Citations
This map shows the geographic impact of Carlos Gomez‐Roca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Gomez‐Roca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Gomez‐Roca more than expected).
Fields of papers citing papers by Carlos Gomez‐Roca
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carlos Gomez‐Roca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Gomez‐Roca. The network helps show where Carlos Gomez‐Roca may publish in the future.
Co-authorship network of co-authors of Carlos Gomez‐Roca
This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Gomez‐Roca. A scholar is included among the top collaborators of Carlos Gomez‐Roca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Gomez‐Roca. Carlos Gomez‐Roca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ascierto, Paolo A., Sonia Dolfi, Marta Nyakas, et al.. (2025). Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. Journal for ImmunoTherapy of Cancer. 13(2). e009773–e009773.
2.
Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411.
3.
Farés, Nadim, et al.. (2024). Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two Cases. Cureus.
4.
Luke, Jason J., Karen A. Gelmon, Lillian L. Siu, et al.. (2024). Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clinical Cancer Research. 31(11). 2134–2144.
5.
Steeghs, Neeltje, Carlos Gomez‐Roca, Eelke Gort, et al.. (2024). Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2573–2573.
6.
Steeghs, Neeltje, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, et al.. (2024). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical Cancer Research. 30(13). 2693–2701.
7.
Gomez‐Roca, Carlos, Sylvie Chabaud, Céline Rodriguez, et al.. (2024). The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science Translational Medicine. 16(731). eadd1834–eadd1834.
8.
Abdeddaim, Cyril, Sophie Cousin, Carlos Gomez‐Roca, et al.. (2023). 758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S518–S518.
9.
Féliu, Virginie, Carlos Gomez‐Roca, Émeline Sarot, et al.. (2023). Distant antimetastatic effect of enterotropic colon cancer–derived α4β7 + CD8 + T cells. Science Immunology. 8(84). eadg8841–eadg8841.
10.
Cousin, Sophie, Coralie Cantarel, Jean‐Philippe Guégan, et al.. (2021). Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clinical Cancer Research. 27(8). 2139–2147.
11.
Tourneau, Christophe Le, Yungan Tao, Carlos Gomez‐Roca, et al.. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 26(24). 6429–6436.
12.
Delord, Jean‐Pierre, Antoîne Italiano, Ahmad Awada, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology. 16(1). 37–46.
13.
Lebbé, Célèste, Antoîne Italiano, Nadine Houédé, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology. 16(1). 47–57.
14.
Martin, Nicolas, Nicolás Isambert, Carlos Gomez‐Roca, et al.. (2018). Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(6). 979–986.
15.
Massabeau, Carole, Jonathan Khalifa, Thomas Filleron, et al.. (2017). Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer. 19(3). e277–e285.
16.
Frenel, Jean‐Sébastien, Christophe Le Tourneau, Bert H. O’Neil, et al.. (2017). Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology. 35(36). 4035–4041.
17.
Stathis, Anastasios, Emanuele Zucca, Mohamed Békradda, et al.. (2016). Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discovery. 6(5). 492–500.
18.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671.
19.
Ferté, Charles, Antoine Hollebecque, Serge Koscielny, et al.. (2013). Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research. 20(1). 246–252.
20.
Rodrigues, Manuel & Carlos Gomez‐Roca. (2013). Place des technologies de séquençage haut débit en oncologie. Bulletin du Cancer. 100(3). 295–301.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Steven J. Lemery Breakdown of academic impact, for papers by Sameek Roychowdhury Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Alexander N. Shoushtari Breakdown of academic impact, for papers by Ulrik Lassen Breakdown of academic impact, for papers by Alejandro D. Ricart Breakdown of academic impact, for papers by Syma Iqbal